iX Biopharma Ltd. (SG:42C) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
iX Biopharma Ltd has reported successful results from a human trial of its SL-NAD+ sublingual wafers, showing a significant increase in blood NAD+ levels, up to 76% over six weeks, and improvements in energy, mood, sleep, mental clarity, and physical strength. The trial, which underscores the potential of NAD+ supplementation for enhancing quality of life, also confirmed the wafers to be safe and well tolerated. The company highlights the product’s superior delivery method and bioavailability as a convenient and effective way to maintain optimal NAD+ levels for healthspan.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.
